ViroGates A/S (CPH:VIRO)

Market Cap	111.85M +7.9%
Revenue (ttm)	8.11M +11.9%
Net Income	-12.39M
EPS	-1.60
Shares Out	9.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,248
Average Volume	1,893
Open	12.65
Previous Close	12.70
Day's Range	12.05 - 13.00
52-Week Range	5.98 - 17.40
Beta	0.91
RSI	51.88
Earnings Date	Mar 26, 2026

About ViroGates

ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2024, ViroGates's revenue was 7.14 million, an increase of 2.22% compared to the previous year's 6.99 million. Losses were -14.35 million, 18.6% more than in 2023.